HCC risk stratification and detection biomarkers tested in the U.S. patient populations

Hepatocellular carcinoma (HCC) mortality remains high in the U.S. due to failed early detection, which is attributable to the low adherence rate to the guideline-recommended ultrasound-based HCC screening. To overcome the challenge, new molecular and imaging biomarkers have been developed for refined risk stratification and early detection. Integration of these new technologies may enable new strategies for HCC screening tailored by estimated HCC risk to refine early detection and maximize cost-effectiveness of the screening. Several prospective studies are currently ongoing to evaluate new HCC screening strategies in the U.S., which will be overviewed in this lecture.